Cite
HARVARD Citation
Hamid, O. et al. (2022). First-in-human study of an OX40 (ivuxolimab) and 4-1BB (utomilumab) agonistic antibody combination in patients with advanced solid tumors. Journal for immunotherapy of cancer. 10 (10), p. . [Online].